Pharmacologic therapy for behavioral symptoms of Alzheimer's disease

Clinics in Geriatric Medicine

Volumn 17, Issue 2, 2001, Pages 359-376

  Tariot, Pierre N ^a   Ryan, J Michael ^a   Porsteinsson, Anton P ^a   Loy, Rebekah ^a   Schneider, Lon S ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGITATION; ALZHEIMER DISEASE; CAREGIVER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; SLEEP DISORDER;

EID: 0035010201     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70073-2     Document Type: Article

References (58)

1. Treatment of agitation in older persons with dementia
2. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
3. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease
4. Buspirone vs. haloperidol: A double-blind trial for agitation in a nursing home population with Alzheimer's disease
5. Carbamazepine in senile dementia and overactivity: A placebo controlled double blind trial
6. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients
7. Neurotransmitter correlates of impulsive aggression in humans
8. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients
9. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated
10. Cholinesterase inhibitors: A new class of psychotropic compounds
11. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
12. Depression in dementia
13. The course of psychopathologic features in mild to moderate Alzheimer disease
14. A randomized, placebo-controlled, dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
15. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment
16. The use of adjunctive divalproex for neuroleptic unresponsive behavioral disturbances in nursing home residents with dementia
17. Nursing interventions for patients with Alzheimer's disease
18. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients
19. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
20. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone
21. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study
22. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
23. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia
24. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease
25. Agitation associated with dementia: A systematic approach to treatment
26. A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia
27. Alzheimer's disease: Behavioral management
28. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on memory in aging
29. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness
30. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
31. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study
32. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease
33. Use of benzodiazepines in behaviorally disturbed patients: Risk-benefit ratio
34. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations
35. Treatment of behaviors in dementia with Citalopram
36. Placebo-controlled study of divalproex sodium for agitation in dementia
37. Long-term treatment of elderly individuals with emotional disturbances: An open study with citalopram
38. Gabapentin for behavioral agitation in Alzheimer's disease
39. Treatments for behavioral and psychological symptoms in Alzheimer's disease and other dementias
40. A clinical update in olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients
41. A meta-analysis of controlled trials of neuroleptic treatment in dementia
42. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients
43. Zolpidem for dementia-related insomnia and nighttime wandering
44. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease
45. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia
46. Sleep disturbances in dementia
47. Treatment of agitation in dementia
48. The psychopathology of dementia
49. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study
50. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
51. Lack of carbamazepine toxicity in frail nursing home patients: A controlled study
52. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. The behavioral pathology committee of the consortium to establish a registry for Alzheimer's disease
53. Safety and divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial
54. A 5-month, randomized placebo-controlled trial of galantamine in AD
55. Long-term use of quehapine in elderly patients with psychotic disorders
56. Age is not a barrier to donepezil treatment of Alzheimer's disease in the long term care setting
57. Treatment of agitation in Alzheimer's disease patients: A randomized placebo controlled clinical trial